Patents by Inventor Petr Alexander

Petr Alexander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240066324
    Abstract: A system includes a cylindrical phantom and a conical structure disposed in the phantom. The conical structure is shaped as a frustum and emits Cherenkov radiation when exposed to ionizing radiation. The system can be used for calibration of an MR-Linac system by exposing the system to ionizing radiation. The Cherenkov radiation can be imaged during exposure to ionizing radiation.
    Type: Application
    Filed: March 7, 2022
    Publication date: February 29, 2024
    Inventors: Daniel A. Alexander, Jacqueline Andreozzi, Petr Bruza, Rongxiao Zhang, David J. Gladstone
  • Patent number: 5767100
    Abstract: In accordance with this invention novel compounds are provided that are selected from saturated and unsaturated pyrans and furans substituted with at least a phosphonate group and a heterocyclic base. These compounds are useful as antiinfectives, flame retardants, diagnostic oligonucleotides and immunogens.
    Type: Grant
    Filed: March 13, 1996
    Date of Patent: June 16, 1998
    Assignee: Gilead Sciences, Inc.
    Inventors: Petr Alexander, Ernest J. Prisbe
  • Patent number: 5756486
    Abstract: The internally cyclized congeners of hydroxy-substituted nucleotide analogues have been found to exhibit substantially lower toxicity in vivo than their uncyclized analogues, while retaining essentially the same antiviral activity. This was unexpected because the prior art suggested that the cyclic analogues offered no significant advantages in respect to toxicity. This finding permits the administration of much greater doses of the cyclic congeners than otherwise would have been possible and allows the clinician to omit toxicity ameliorating interventions. Novel compounds are provided for use in the method of this invention. Novel methods for the preparation of these compounds also are provided.
    Type: Grant
    Filed: September 5, 1996
    Date of Patent: May 26, 1998
    Assignee: Gilead Sciences, Inc.
    Inventors: Petr Alexander, Murty Arimilli, Norbert Bischofberger, Michael J. M. Hitchcock
  • Patent number: 5750729
    Abstract: In accordance with this invention novel compounds are provided that are selected from saturated and unsaturated pyrans and furans substituted with at least a phosphonate group and a heterocyclic base. These compounds are useful as antiinfectives, flame retardants, diagnostic oligonucleotides and immunogens.
    Type: Grant
    Filed: February 25, 1997
    Date of Patent: May 12, 1998
    Assignee: Gilead Sciences,Inc.
    Inventors: Petr Alexander, Ernest J. Prisbe
  • Patent number: 5693771
    Abstract: In accordance with this invention novel compounds are provided that are selected from saturated and unsaturated pyrans and furans substituted with at least a phosphonate group and a heterocyclic base. These compounds are useful as antiinfectives, flame retardants, diagnostic oligonucleotides and immunogens.
    Type: Grant
    Filed: March 13, 1996
    Date of Patent: December 2, 1997
    Assignee: Gilead Sciences, Inc.
    Inventors: Petr Alexander, Ernest J. Prisbe
  • Patent number: 5659023
    Abstract: In accordance with this invention novel compounds are provided that are selected from saturated and unsaturated pyrans and furans substituted with at least a phosphonate group and a heterocyclic base. These compounds are useful as antiinfectives, flame retardants, diagnostic oligonucleotides and immunogens.
    Type: Grant
    Filed: February 1, 1995
    Date of Patent: August 19, 1997
    Assignee: Gilead Sciences, Inc.
    Inventors: Petr Alexander, Ernest J. Prisbe
  • Patent number: 5591851
    Abstract: The internally cyclized congeners of hydroxy-substituted nucleotide analogues have been found to exhibit substantially lower toxicity in vivo than their uncyclized analogues, while retaining essentially the same antiviral activity. This was unexpected because the prior art suggested that the cyclic analogues offered no significant advantages in respect to toxicity. This finding permits the administration of much greater doses of the cyclic congeners than otherwise would have been possible and allows the clinician to omit toxicity ameliorating interventions. Novel compounds are provided for use in the method of this invention. Novel methods for the preparation of these compounds also are provided.
    Type: Grant
    Filed: February 5, 1996
    Date of Patent: January 7, 1997
    Assignee: Gilead Sciences, Inc.
    Inventor: Petr Alexander
  • Patent number: 5130427
    Abstract: The invention relates to the new compound (2R)-2-[di(2-propyl)phosphonylmethoxy]-3-p-toluenesulfonyloxy-1-trimethyla cetoxypropane and the method of producing it. The compound may be used for producing (S)-N-(3-hydroxy-2-phosphonylmethoxypropyl) derivatives of the heterocyclic purine and pyrimidine bases of antiviral activity.
    Type: Grant
    Filed: July 12, 1991
    Date of Patent: July 14, 1992
    Assignee: Ceskoslovenska akademie ved
    Inventors: Petr Alexander, Antonin Holy, Hana Dvorakova
  • Patent number: RE35558
    Abstract: The invention relates to the new compound (2R)-2-[di(2-propyl)phosphonylmethoxy]-3-p-toluenesulfonyloxy-1-trimethyla cetoxypropane and the method of producing it. The compound may be used for producing (S)-N-(3-hydroxy-2-phosphonylmethoxypropyl) derivatives of the heterocyclic purine and pyrimidine bases of antiviral activity.
    Type: Grant
    Filed: July 14, 1994
    Date of Patent: July 8, 1997
    Assignee: Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic
    Inventors: Petr Alexander, Antonin Holy, Hana Dvorakova